iifl-logo

Jubilant Pharmova Ltd Historical Data

Add as a Preferred Source on Google
937.65
(-3.72%)
Feb 6, 2026|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Jubilant Pharmova Ltd Historical Data

09/01/2026calendar-icon
09/02/2026calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

12-Jan-2026

1,063

1,065.41,019.11,050.515,35512,60,26,222.350,786

13-Jan-2026

1,044

1,0511,034.71,040.614,68312,69,56,741.261,742

14-Jan-2026

1,031.1

1,0731,031.11,066.313,14310,42,66,932.147,493

16-Jan-2026

1,055.7

1,067.91,0401,045.69,8176,29,97,666.625,401

19-Jan-2026

1,031

1,032983.6994.520,29120,76,45,696.892,623

20-Jan-2026

994

996944.6950.816,21718,56,80,059.696,357

21-Jan-2026

942.2

961.7932.6946.827,96434,47,44,924.72,17,311

22-Jan-2026

954.9

973.6952.19687,6275,22,60,240.729,079

23-Jan-2026

968

969.5926.9956.112,94213,29,19,023.376,812

27-Jan-2026

951

955.9929.6938.912,6599,15,54,494.942,050

28-Jan-2026

940.9

970937.4962.213,0987,69,65,967.342,552

29-Jan-2026

965

966.1931938.115,54213,67,41,879.875,008

30-Jan-2026

942

991930981.917,19615,21,01,212.375,204

01-Feb-2026

981.9

985.35948.3967.856,1714,76,28,731.8520,139

02-Feb-2026

959.1

969.05930.15957.7510,4298,64,37,737.441,656

03-Feb-2026

996

998.35965.5988.7511,54014,58,71,371.1583,924

04-Feb-2026

981.5

991965.6969.858,4836,48,36,513.6532,571

05-Feb-2026

972.95

977.6957.45973.854,4813,59,49,295.115,911

06-Feb-2026

973.85

976.4929.6937.6532,52136,90,77,803.474,240

Jubilant Pharmo: Related NEWS

Jubilant Pharmova to sale API business to Jubilant Biosys

The API division posted a turnover of ₹609 Crore for the financial year ended March 2025. This was 8.35% of the company’s consolidated revenue.

13 Jun 2025|12:29 PM
Read More
Top Stocks for Today - 13th June 2025

Here are some of the stocks that may see significant price movement today: Torrent Power, DCM Shriram, Jubilant Pharmova, etc.

13 Jun 2025|06:37 AM
Read More
Jubilant Pharmova Passes FDA Audit, Expands R&D with Pierre Fabre

This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.

26 Sep 2024|07:42 PM
Read More
FDA Issues VAI Status to Jubilant HollisterStier's Washington Facility

Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.

11 Sep 2024|11:23 AM
Read More
Top 10 stocks for today – 11th September, 2024

Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.

11 Sep 2024|09:23 AM
Read More
Jubilant Pharmova arm to pick up 80% stake in Pierre Fabre’s centre

Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.

19 Aug 2024|01:36 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.